The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Characterization and peripheral blood biomarker assessment of anti–Jo‐1 antibody–positive interstitial lung disease
Open accessAbstract
Objective: Using a combination of clinical, radiographic, functional, and serum protein biomarker assessments, this study was aimed at defining the prevalence and clinical characteristics of interstitial lung disease (ILD) in a large cohort of patients with anti–Jo‐1 antibodies. Methods: A review of clinical records, pulmonary function test results, and findings on imaging studies determined the existence of ILD in anti–Jo‐1 antibody–positive individuals whose data were accumulated in the University of Pittsburgh Myositis Database from 1982 to 2007. Multiplex enzyme‐linked immunosorbent assays (ELISAs) for serum inflammation markers, cytokines, chemokines, and matrix metalloproteinases in different patient subgroups were performed to assess the serum proteins associated with anti–Jo‐1 antibody–positive ILD. Results: Among the 90 anti–Jo‐1 antibody–positive individuals with sufficient clinical, radiographic, and/or pulmonary function data, 77 (86%) met the criteria for ILD. While computed tomography scans revealed a variety of patterns suggestive of underlying usual interstitial pneumonia (UIP) or nonspecific interstitial pneumonia, a review of the histopathologic abnormalities in a subset of patients undergoing open lung biopsy or transplantation or whose lung tissue was obtained at autopsy (n = 22) demonstrated a preponderance of UIP and diffuse alveolar damage. Analysis by multiplex ELISA yielded statistically significant associations between anti–Jo‐1 antibody–positive ILD and elevated serum levels of C‐reactive protein (CRP), CXCL9, and CXCL10, which distinguished this disease entity from idiopathic pulmonary fibrosis and anti–signal recognition particle antibody–positive myositis. Recursive partitioning further demonstrated that combinations of these and other serum protein biomarkers can distinguish these disease subgroups at high levels of sensitivity and specificity. Conclusion: In this large cohort of anti–Jo‐1 antibody–positive individuals, the incidence of ILD approached 90%. Multiplex ELISA demonstrated disease‐specific associations between anti–Jo‐1 antibody–positive ILD and serum levels of CRP as well as the interferon‐γ–inducible chemokines CXCL9 and CXCL10, highlighting the potential of this approach to define biologically active molecules contributing to the pathogenesis of myositis‐associated ILD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Acute Exacerbations of Idiopathic Pulmonary Fibrosis
Collard, H. R., Moore, B. B., Flaherty, K. R., Brown, K. K., Kaner, R. J., King, T. E., Lasky, J. A., Loyd, J. E., Noth, I., Olman, M. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-463pp · Cited by 1,130
Self-citation
Cited by
Interstitial Lung Disease Associated With the Idiopathic Inflammatory Myopathies
Connors, G. R., Christopher-Stine, L., Oddis, C. V., & Danoff, S. K. (2010) · Chest · doi:10.1378/chest.10-0180 · Cited by 564
Self-citationAggarwal, R., Cassidy, E., Fertig, N., Koontz, D. C., Lucas, M., Ascherman, D. P., & Oddis, C. V. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-201800 · Cited by 301
Self-citationKahloon, R. A., Xue, J., Bhargava, A., Csizmadia, E., Otterbein, L., Kass, D. J., Bon, J., Soejima, M., Levesque, M. C., Lindell, K. O., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201203-0506oc · Cited by 190
Self-citation
Metadata
- Authors
- Richards, T. J., Eggebeen, A., Gibson, K., Yousem, S., Fuhrman, C., Gochuico, B. R., Fertig, N., Oddis, C. V., Kaminski, N., Rosas, I. O., & Ascherman, D. P.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2009-06-29
- Volume
- 60
- Issue
- 7
- Pages
- 2183-2192
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2054352916
- Cited by
- 158
- References
- 1
- FWCI
- 5.55
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.